Soligenix receives $1.4m in non-dilutive government funding

Princeton, n.j. , april 19, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $1.4 million, net of transaction costs, in non-dilutive funding via multiple government tax programs.
SNGX Ratings Summary
SNGX Quant Ranking